Swiss startup Cytosurge and Olympus, the leading manufacturer of high-end research microscopes have signed a co-marketing agreement to deliver a complete single-cell and crispr genetic manipulation solution in the Americas. The FluidFM® BOT BIO Series combines Olympus’ renowned optics with Cytosurge’s cell manipulation expertise.
Cytosurge develops, manufactures, and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM technology. At the heart of the technology are the hollow FluidFM probes, which have apertures down to 300 nm, enabling the handling of femtoliter volumes.
The startup provides a powerful genetic manipulation solution with the FluidFM BOT BIO Series, a highly automated system built on the Olympus IX83 inverted microscope with Olympus’ renowned optics. In addition to CRISPR genome editing, the system’s core functionalities—intracellular- and nuclear- injection and extraction, pick-and-place at the microscale, and precise dispensing of liquids—enable a broad range of applications, including single-cell drug assays, monoclonal cell line development and nano.printing of custom patterns.
“We are very excited to formalize a partnership with Cytosurge, as we have worked with them for many years,” said Lee Wagstaff, Vice President of Life Science Sales and Marketing at Olympus Corporation of the Americas. “With the FluidFM BOT BIO Series, we see tremendous potential for continued collaboration to blend our optical technologies with their high-precision cell manipulation technologies.”
“The USA was the last missing key market in Cytosurge’s strategic development plan to cover the globe. Our new partnership with Olympus Corporation of the Americas epitomizes the objectives and values of our company, embodying a very high level of understanding and mutual trust. Everything is ready for a rapid and effective market launch to make our remarkable FluidFM technology available on the American continent. With this, we are empowering researchers in both academia and the private sector to go beyond current technological barriers and help them bring new, much-needed therapies and medications to the market faster,” said Cytosurge CEO Pascal Behr.
Olympus develops solutions for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, the company has been supporting people’s wellbeing by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.